Literature DB >> 11920484

Combined chemotherapy and radiation therapy for head and neck malignancies: quality of life issues.

Nam P Nguyen1, Sabah Sallah, Ulf Karlsson, John E Antoine.   

Abstract

BACKGROUND: The standard of care for locally advanced head and neck carcinoma usually has been surgery followed by radiation therapy. Patient survival using this approach has been reported to be poor. The disfiguration resulting from surgery and the long-term morbidity of postoperative radiation often results in considerable distress. Concurrent chemotherapy and radiation was introduced to improve outcome. Excellent local control and survival results often have been reported in Phase II and Phase III studies. The acute toxicity of combined chemotherapy and radiation is significant. However, organ preservation may improve quality of life. This review article summarizes the findings from published series of surgery, postoperative radiation, radiation therapy alone, and chemoradiation with regard to quality of life issues for patients with locally advanced head and neck carcinoma.
METHODS: A literature search was used to identify quality-of-life studies of postoperative radiation, radiation therapy alone, and chemoradiation in patients with locally advanced head and neck carcinoma. Factors affecting long-term quality-of-life issues in each treatment modality were identified, compared, and evaluated.
RESULTS: Speech disorder, dysphagia, pain, and depression were found to be the common side effects affecting quality of life regardless of the treatment modality. Xerostomia is the major complication affecting patients undergoing radiation or chemoradiation.
CONCLUSIONS: Acute side effects of combined chemotherapy and radiation therapy usually were found to resolve after treatment. Long-term morbidity is substantial because of xerostomia and severe dysphagia. However, preliminary studies suggest that because of organ preservation, patients may achieve a better quality of life after chemoradiation compared with the conventional use of surgery and postoperative radiation. Copyright 2002 American Cancer Society. DOI 10.1002/cncr.10257

Entities:  

Mesh:

Year:  2002        PMID: 11920484     DOI: 10.1002/cncr.10257

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  49 in total

1.  Acupuncture for dysphagia after chemoradiation in head and neck cancer: rationale and design of a randomized, sham-controlled trial.

Authors:  Weidong Lu; Peter M Wayne; Roger B Davis; Julie E Buring; Hailun Li; Laura A Goguen; David S Rosenthal; Roy B Tishler; Marshall R Posner; Robert I Haddad
Journal:  Contemp Clin Trials       Date:  2012-03-02       Impact factor: 2.226

2.  Association between severity of dysphagia and survival in patients with head and neck cancer.

Authors:  Samantha E Shune; Lucy Hynds Karnell; Michael P Karnell; Douglas J Van Daele; Gerry F Funk
Journal:  Head Neck       Date:  2011-08-30       Impact factor: 3.147

3.  Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence.

Authors:  Krystle A Lang Kuhs; Aimée R Kreimer; Sumita Trivedi; Dana Holzinger; Michael Pawlita; Ruth M Pfeiffer; Sandra P Gibson; Nicole C Schmitt; Allan Hildesheim; Tim Waterboer; Robert L Ferris
Journal:  Cancer       Date:  2017-09-26       Impact factor: 6.860

Review 4.  A comparison of swallowing dysfunction after three-dimensional conformal and intensity-modulated radiotherapy : A systematic review by the Italian Head and Neck Radiotherapy Study Group.

Authors:  Stefano Ursino; Elisa D'Angelo; Rosario Mazzola; Anna Merlotti; Riccardo Morganti; Agostino Cristaudo; Fabiola Paiar; Daniela Musio; Daniela Alterio; Almalina Bacigalupo; Elvio Grazioso Russi; Frank Lohr
Journal:  Strahlenther Onkol       Date:  2017-06-14       Impact factor: 3.621

Review 5.  Systematic review of dose--volume correlates for structures related to late swallowing disturbances after radiotherapy for head and neck cancer.

Authors:  Fréderic Duprez; Indira Madani; Bruno De Potter; Tom Boterberg; Wilfried De Neve
Journal:  Dysphagia       Date:  2013-02-22       Impact factor: 3.438

6.  Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy.

Authors:  Maria B Koenigs; Armida Lefranc-Torres; Juliana Bonilla-Velez; Krupal B Patel; D Neil Hayes; Krzysztof Glomski; Paul M Busse; Annie W Chan; John R Clark; Daniel G Deschler; Kevin S Emerick; Rebecca J Hammon; Lori J Wirth; Derrick T Lin; Edmund A Mroz; William C Faquin; James W Rocco
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

Review 7.  Interobserver variation in parotid gland delineation: a study of its impact on intensity-modulated radiotherapy solutions with a systematic review of the literature.

Authors:  S W Loo; W M C Martin; P Smith; S Cherian; T W Roques
Journal:  Br J Radiol       Date:  2012-08       Impact factor: 3.039

8.  Delineating brachial plexus, cochlea, pharyngeal constrictor muscles and optic chiasm in head and neck radiotherapy: a CT-based model atlas.

Authors:  Domenico Genovesi; Francesca Perrotti; Marianna Trignani; Angelo Di Pilla; Annamaria Vinciguerra; Antonietta Augurio; Monica Di Tommaso; Massimo Caulo; Massimo Savastano; Armando Tartaro; Antonio Raffaele Cotroneo; Giampiero Ausili Cèfaro
Journal:  Radiol Med       Date:  2014-08-05       Impact factor: 3.469

9.  Two-stage autotransplantation of human submandibular gland: a novel approach to treat postradiogenic xerostomia.

Authors:  Rudolf Hagen; Matthias Scheich; Norbert Kleinsasser; Marc Burghartz
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-08-19       Impact factor: 2.503

Review 10.  Functional outcomes and rehabilitation strategies in patients treated with chemoradiotherapy for advanced head and neck cancer: a systematic review.

Authors:  Lisette van der Molen; Maya A van Rossum; Lori M Burkhead; Ludi E Smeele; Frans J M Hilgers
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-09-30       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.